Compare Quest Diagnostics Inc (DGX) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Star Bulk Carriers Corp — how do they compare? Quest Diagnostics Inc trades at $237.52 (market cap $26.21B), while Star Bulk Carriers Corp trades at $27.73 (market cap $3.09B). The key difference: Quest Diagnostics Inc is far larger — about 8.5× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.79%). Which is the better fit depends on your goals.
| DGX | SBLK | |
|---|---|---|
Market Cap | $26.21B | $3.09B |
Sector | Health | Industrials |
52-Week High | $238.50 | $29.15 |
52-Week Low | $173.49 | $16.79 |
Enterprise Value | $31.97B | $3.77B |
Dividend Yield | 1.45% | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Star Bulk Carriers (SBLK) trades at $27.80, down 2.18% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported robust Q2 2026 results with net income of $144.9 million and declared a $0.90 dividend, reflecting operational strength. Revenue grew to $1.2 billion in 2026, with net profit margin expanding to 23.86%, while valuation ratios like P/E of 10.85 and EV/EBITDA of 7.46 suggest reasonable pricing. Recent news highlights termination of a vessel agreement with Diana Shipping, but operational updates remain positive.
SBLK presents a favorable outlook with earnings momentum, high dividend yield, and analyst buy consensus, though risks include dry bulk rate volatility and competitive pressures. The stock's fundamental health supports potential upside, but investors should weigh cyclical industry exposure against strong cash flow generation and balance sheet flexibility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
